Meditinib Sulfate

硫酸美迪替尼

Report date: 2022/02/28 15:33:23
NME

Base Information

Drug NameMeditinib Sulfate
Drug Alias NameSX-004
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase SRC inhibitorsBcr-Abl tyrosine kinase inhibitors
TargetsTyrosine-protein kinase SRCBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHarbin Gloria Pharmaceuticals Co LtdBeijing Medisys Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHarbin Gloria Pharmaceuticals Co LtdBeijing Meidi Kangxin Pharmaceutical Technology Co LtdBeijing Medisys Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A